- Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, has expanded its team with two clinical research associates
- Bhavya Bajantri and Sonia Keshwani are tasked with completing the ongoing Phase II bladder cancer clinical study testing Ruvidar (TLD-1433), Theralase’s drug candidate to destroy solid tumors using its photo dynamic compound technology
- Theralase is a clinical-stage pharmaceutical stock focused on safely and thoroughly destroying various cancers, bacteria and viruses
- Theralase stock has given back 28.26 per cent year-over-year, and 64.89 per cent since 2019
Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, has expanded its team with two clinical research associates.
Bhavya Bajantri M.Sc., CCRP, and Sonia Keshwani B.Sc., CCRP, were onboarded effective March 4 and May 1, 2024, respectively, to help to complete the ongoing Phase II bladder cancer…
